Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Moscat J, Cuervo AM, Diaz-Meco MT. Immunosurveillance, interferon, and autophagic networking in cancer: the PRKCI-ULK2 paradigm. Autophagy. 2022;18(1):226-227.

Hernandez-Prera JC, Saeed-Vafa D, Heidarian A, Gewandter K, Otto K, Wenig BM. Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature. Head Neck Pathol. 2022;16(2):416-426.

Papke DJ, Lindeman NI, Schrag D, J Iorgulescu B. Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1746-1751.

Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, et al. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2022;21(10):103158.

Buyukozkan M, Alvarez-Mulett S, Racanelli AC, Schmidt F, Batra R, Hoffman KL, et al. Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. iScience. 2022;25(7):104612.

Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, et al. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022;40(35):4119-4128.

Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, et al. Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. NPJ Precis Oncol. 2022;6(1):33.

Panarelli NC. In Reply. Arch Pathol Lab Med. 2022;146(10):1182a-1182.

Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, et al. A multidisciplinary approach to optimize primary prostate cancer biobanking. Urol Oncol. 2022;40(6):271.e1-271.e7.

Cayrol F, Revuelta MV, Debernardi M, Paulazo A, Phillip JM, Zamponi N, et al. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2022;21(9):1485-1496.